Chylous ascites

Summary

Chylous ascites (MONDO:0008829) is a disease and 1 clinical trial. Top therapeutic interventions include iohexol and iopamidol. A subtype of primary lymphedema — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 7
• Clinical trials: 1

Clinical features

Signs & symptoms

Clinical features (HPO)

7 HPO clinical features (Orphanet curated; top 7 by frequency):

HPO ID	Term	Frequency
HP:0001004	Lymphedema	Very frequent (80-99%)
HP:0001541	Ascites	Very frequent (80-99%)
HP:0001482	Subcutaneous nodule	Frequent (30-79%)
HP:0000501	Glaucoma	Occasional (5-29%)
HP:0001733	Pancreatitis	Occasional (5-29%)
HP:0002242	Abnormal intestine morphology	Occasional (5-29%)
HP:0002664	Neoplasm	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	chylous ascites
Mondo ID	MONDO:0008829
MeSH	D002915
OMIM	208300
Orphanet	1160
ICD-11	768846885
NCIT	C34482
SNOMED CT	52985009
UMLS	C0008732
MedGen	969
GARD	0001359
MedDRA	10003446
Is cancer (heuristic)	no

Also known as: congenital chylous ascites

Disease family

This is a subtype of primary lymphedema. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › lymphoid system disorder › lymphatic system disorder › lymphedema › primary lymphedema › chylous ascites

Related subtypes (12): hypotrichosis-lymphedema-telangiectasia syndrome (grouping), aplasia cutis congenita-intestinal lymphangiectasia syndrome, Aagenaes syndrome, German syndrome, mullerian derivatives-lymphangiectasia-polydactyly syndrome, congenital pulmonary lymphangiectasia, lymphedema-atrial septal defects-facial changes syndrome, lymphatic malformation, GJC2-related late-onset primary lymphedema, warts-immunodeficiency-lymphedema-anogenital dysplasia syndrome, EPHB4-related lymphatic-related hydrops fetalis, CELSR1-related late-onset primary lymphedema

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06820320	PHASE2	COMPLETED	Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IOHEXOL	4	1
IOPAMIDOL	4	1
CHEMBL1335195	0	1